Article Text

Download PDFPDF
Use of BCG as an immunostimulant in the surgical treatment of carcinoma of lung: a five-year follow-up report.
  1. F R Edwards,
  2. F Whitwell

    Abstract

    Sixty consecutive surviving patients treated with subdermal BCG (5 X 10(6) organisms) have been followed up for five years after resection of lung carcinoma. A control group of the previous 60 consecutive surviving patients not treated with BCG was similarly studied. We found no statistical evidence that the administration of BCG by the method described influenced the five-year survival rate, nor has any effective action upon involved lymph nodes or small metastases been demonstrated.

    Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.